amenorrheic for the past 3 months. She was diagnosed with hypothyroidism two years ago and was taking levothyroxine 100 lg daily.
Her examination revealed hyperpigmentation of the tip of the nose and alae nasi. Bilateral posterior cervical lymphadenopathy was present with the largest node measuring 1.5 cm. The spleen was palpable 11 cm below the left costal margin and 17 cm below the xyphoid. A pericardial rub was audible.
Her Hb was 5.9 g/dL, leukocytes 2.5 9 10 9 /L, platelets 180 9 10 9 /L and reticulocytes 0.8 %. Blood smear examination showed normal red cell morphology and absence of leukoerythroblastosis. Urinalysis showed normal findings. Serum creatinine, total bilirubin, lactate dehydrogenase and TSH were within normal limits. The serum total protein was 9.6 g/dL and globulin 7.0 g/dL. Protein electrophoresis showed polyclonal hyperglobulinemia. Screen for antinuclear antibodies was positive. Anti-ds-DNA, antiSm, anti-RNP and anti-SSB antibodies were strongly positive. The direct antiglobulin test (DAT) was positive. The results of ELISA for HIV antibodies and a Montoux tuberculin skin test were negative. Computed tomographic scan of abdomen showed marked splenomegaly measuring 22 cm and pericardial effusion (Fig. 1 ). An excisional biopsy of cervical lymph node showed non-specific changes. Both pleural and ascitic fluid were transudates.
Bone marrow aspiration yielded extremely scanty material that showed areas of small lymphocyte infiltration (Fig. 2a) ; marrow trephine biopsy showed hypercellular marrow, non-clustered megakaryocytes, normoblastic erythroid hyperplasia, normal myelopoiesis and grade-3 (modified Bauermeister scale) reticulin fibrosis (Fig. 2b) . A test for JAK2 V617F mutation gave a negative result.
She was started on 1.5 mg/kg/d of prednisone. After 5 weeks of steroid therapy she was asymptomatic; the lymph nodes and spleen were not palpable. Her Hb increased to 12.4 g/dL and leukocytes increased to 13 9 10 9 /L. A bone marrow biopsy done after 7 weeks of steroid therapy showed normal marrow morphology and grade-1 reticulin fibrosis (Fig. 2c) ; a repeat DAT result was negative. The total serum protein was 7.1 g/dL and serum globulin 3.1 g/dL. One year following her initial diagnosis with SLE-AIMF she developed proteinuria (4 g/24 h) and was diagnosed with membranoproliferative glomerulonephritis. Her spleen remains non-palpable.
Case 2
A 23-year-old woman was admitted to the Hospital with a dry cough and fever of 2 weeks' duration. One week before admission she developed puffiness of face, pedal edema and abdominal distention. Her past history was of hypothyroidism diagnosed 2 years previously. Her menstrual history was normal.
She was acutely ill, pale and febrile. She had a puffy face, pedal edema and ascites. There was no lymphadenopathy or splenomegaly.
Her Hb was 6.5 g/dL, leukocytes 6.0 9 10 9 /L with normal differential count, platelets 22 9 10 9 /L and reticulocytes 0.8 %. Blood smear examination showed normal red cell morphology and no nucleated red cells or immature myeloid cells. Results of urinalysis and liver function tests were normal. The serum creatinine was 1.0 mg/dL, lactate dehydrogenase 597 U/L, serum ferritin 1309 ng/mL and TSH 43 lIU/L. An ELISA for anti-nuclear antibodies was strongly positive; test for anti-ds-DNA antibodies and DAT were negative. The C3 complement level was normal. The results of ELISA for HIV antibodies were negative. Blood and urine cultures remained sterile.
Multiple attempts at bone marrow aspiration resulted in a dry-tap. Examination of marrow trephine biopsy showed normocellular marrow, increased non-clustered megakaryocytes, normal erythro-myelopoiesis, areas of stromal edema with dilated sinusoids and serous degeneration. Reticulin stain showed grade-3 (modified Bauermeister scale) reticulin fibrosis (Fig. 2d) .
She was treated with packed red cell transfusion, amoxicillin-clavulanate and 2 mg/kg/d prednisone. There was prompt resolution of ascites, pleural effusion and pedal edema suggestive of capillary leak syndrome. She was discharged on the sixth hospital day. Following 3 weeks of steroid therapy she was asymptomatic. Her Hb was 10.5 g/dL, leukocytes 11.2 9 10 9 /L, and platelets 120 9 10 9 /L. At her 6-month follow-up she complained of malar rash and photosensitivity. Results of her complete blood count were normal. She was started on hydroxychloroquine 200 mg daily and continues to do well on prednisone 5 mg daily.
Discussion
The clinical and laboratory findings in our patients fulfill the 1997 update of the ARA criteria and the 2012 Systemic Lupus International Collaborating Clinics (SLICC) criteria for the diagnosis of SLE [9] ; the presence of bone marrow reticulin fibrosis and absence of other causes of bone marrow fibrosis established the diagnosis of SLE-AIMF in our patients.
The two patients reported here bring the number of patients with SLE-AIMF reported in the literature to 32 ( Table 1 ). The mean age of the patients with SLE-AIMF was 34 years (range 12-70 years) and 28 were female as expected in SLE. Patients with primary-AIMF are older with a mean age of 52 years [4] [5] [6] [7] [8] .
Seventeen of 32 patients had pancytopenia and 13 patients had bicytopenia (40 %). Thrombocytopenia was present in all but two patients (patients 9 and 31, Table 1) ; splenomegaly was present in 14 of 29 patients (48 %). The prevalence of splenomegaly and thrombocytopenia is much lower (15 %) in unselected patients with SLE [10] . The DAT was positive in 10 out of 20 patients, three of whom had overt hemolytic anemia (patients 14, 19 and 27).
Hematological response to steroid therapy was observed in all but three patients (patients 13, 15 and 16, Table 1 ) and occurred within 2 weeks of starting treatment in a third of the patients. Six patients required IVIG, cyclophosphamide or azathioprine in addition to corticosteroids for response.
Although marked splenomegaly has been considered as an exclusion criterion for the diagnosis of AIMF [4, 5] our patient (case 1) had massive splenomegaly that regressed rapidly with steroid therapy; experience with two other similar cases [7, 11] suggests that marked splenomegaly that regresses rapidly following steroid therapy may be a rare manifestation of AIMF. Small hypolobated bone marrow megakaryocytes described by Bass et al. [4] in patients with primary-AIMF are not a feature of SLE-AIMF. Paquette et al. [3] described clustered megakaryocytes in bone marrow biopsies as an ''invariable'' feature in SLE-AIMF. Subsequent reports make no mention of megakaryocyte clustering in bone marrow biopsies in SLE-AIMF. Some of these inconsistencies may be related to the small number of patients studied.
Reactive lymphoid infiltration of the marrow is considered by some investigators to be one of the required criteria for the diagnosis of primary-AIMF [4, 5] . This finding was present in only four of the 32 patients with SLE-AIMF (patients 1, 24, 27 and 31).
Bone marrow fibrosis was qualified as collagen fibrosis in eight patients, as reticulin fibrosis in 21 patients and not further specified in three. Regression of collagen fibrosis occurred following steroid therapy (with IVIG added in two cases) in four of the nine patients (Table 1) . Regression of reticulin fibrosis with steroid therapy occurred in 10 of the 13 patients in whom bone marrow biopsy was repeated. The development of bone marrow fibrosis may not be related to the duration of prior SLE. The diagnosis of SLE was made concomitantly with the diagnosis of bone marrow fibrosis in 18 of 32 patients. The duration of SLE prior to the diagnosis of AIMF in the others ranged from 9 months to 15 years.
The reported prevalence of increased marrow reticulin in SLE patients with blood cytopenia ranged from 12 % [12] to more than 67 % [13, 14] . Feng et al. [15] reported bone marrow abnormalities in 23 patients with SLE and pancytopenia; no mention is made of bone marrow fibrosis in the patients studied. The reason for the wide variation in the reported prevalence of bone marrow fibrosis in these reports is not clear.
The relative contributions of fibrosis per se and the underlying disease (SLE) to the bone marrow dysfunction remain unclear [1] . The impact of AIMF on the course of the disease (SLE) if any is not clear due to limited clinical information and short follow-up in many patients.
Clinical and experimental data suggest common and overlapping pathogenic mechanisms of fibrogenesis in various organs including the bone marrow [16, 17] . The activation of fibroblasts to myofibroblasts is mediated by cytokines and chemokines. Principal among these are transforming growth factor beta (TGF-b) and platelet derived growth factor (PDGF). Immune complexes, uncharacterized autoantibodies, or inflammatory cytokines might interact with megakaryocytes and result in secretion of profibrotic substances, principally TGF-b that activate resident fibroblasts to secrete reticulin and collagen.
Circulating immune complexes have been implicated in the fibrogenic response in chronic idiopathic myelofibrosis as far back as 1981 [18] . Barcellini et al. [19] recently reported increased incidence of autoimmune markers and elevated levels of TGF-b in chronic idiopathic myelofibrosis. Elevated serum levels of TGF-b and a marked increase in TGF-b production by blood monocytes have been described recently in a patient with primary-AIMF [20] .
The rarity of reports of AIMF in SLE lacks a clear explanation. Under-diagnosis may be a part explanation because it has not been systematically investigated [2] . Genetic and epigenetic factors have been invoked to explain individual susceptibility to fibrosis. Results of studies exploring the link between TGF-b polymorphisms and fibrosis susceptibility have been conflicting [21] .
